Shopping Cart
Remove All
Your shopping cart is currently empty
Orilanolimab (Synonyms: SYNT001, SYNT 001, ALXN1830, ALXN 1830)
Catalog No. T78325 Copy Product Info
Purity: 95%
🥰Excellent
Orilanolimab (SYNT 001, ALXN 1830) is a humanised and deimmunised monoclonal antibody targeting FcRn, disrupting the interaction between FcRn and IgG, and may be used in immunology research.
Orilanolimab
Copy Product Info🥰Excellent
Catalog No. T78325
Synonyms SYNT001, SYNT 001, ALXN1830, ALXN 1830
Orilanolimab (SYNT 001, ALXN 1830) is a humanised and deimmunised monoclonal antibody targeting FcRn, disrupting the interaction between FcRn and IgG, and may be used in immunology research.
Cas No. 2066544-85-0
Customer service consultation
| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 1 mg | $455 | - | In Stock | |
| 5 mg | $1,180 | - | In Stock | |
| 10 mg | $1,890 | - | In Stock | |
| 25 mg | $2,820 | - | In Stock | |
| 50 mg | $3,780 | - | In Stock |
For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)
Add to Cart
Add to Quotation
With extensive experience in compound synthesis, we can provide rapid custom synthesis services for this product according to your research needs.
For research use only—not for human use. No sales to individuals. Use as intended only.
Batch Information
Select Batch
Purity:95.3% (SDS-PAGE); 97.0% (SEC-HPLC)
Appearance:Liquid
Color:Transparent
Contact us for more batch information
Resource Download
Product Introduction
Bioactivity
Related Conjugates and Formulations
Antigen Details
Chemical Properties
Antibody Information
Storage & Solubility Information
| Description | Orilanolimab (SYNT 001, ALXN 1830) is a humanised and deimmunised monoclonal antibody targeting FcRn, disrupting the interaction between FcRn and IgG, and may be used in immunology research. |
| In vitro | In primary CD11c+ APCs derived from B2MTG/TGFCGRTTG/TG Fcgrt-/- mice, Orilanolimab (10nM, 50nM, and 100nM，48 hours) suppressed IFN-γ secretion by OVA-specific CD8+ and CD4+ T cells [1]. |
| In vivo | In hFcRn-expressing mouse models, Orilanolimab (20 mg/kg, intravenous injection) significantly reduced the levels of human IgG and IgG ICs in plasma [1]. Orilanolimab (10, 30, 100 mg/kg, intravenous injection, once weekly) induced a dose-dependent and proposed reduction in total circulating IgG levels in cynomolgus monkeys [1]. |
| Synonyms | SYNT001, SYNT 001, ALXN1830, ALXN 1830 |
| Reactivity | Human |
| Application | Functional assay |
| Antibody Type | Monoclonal |
| Formulation | Supplied as a sterile solution in a buffered formulation system (e.g., phosphate-, citrate-, or amino acid-based). Please refer to the CoA for lot-specific composition. |
| Endotoxin | <1.0 EU/mg |
| Conjucates | Unconjugated |
| Gene ID | |
| Uniprot ID | |
| Target | FcRn (FCGRT & B2M) |
| Molecular Weight | 144.02 kDa |
| Cas No. | 2066544-85-0 |
| Isotype | IgG1 |
| Storage | Store at -20°C Shipping with blue ice/Shipping at ambient temperature. |
Citations
Calculator
Keywords
Preview
Related Tags: buy Orilanolimab | purchase Orilanolimab | Orilanolimab cost | order Orilanolimab | Orilanolimab chemical structure | Orilanolimab in vivo | Orilanolimab in vitro | Orilanolimab molecular weight
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.